In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America

Gales, Ana Cristina; Jones, Ronald N.; Andrade, Sheila Siqueira; Pereira, Andrea dos Santos; Sader, Hélio S.

doi:10.1590/s1413-86702005000500001

Cited by 24 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, the prevalence of ␤ -lactamase producers was 86.9%. H. influenzae and M. catarrhalis were uniformly susceptible to tigecycline, regardless of ␤ -lactamase production, and our results agree with previous international in vitro studies [4,5,17,18,25] .…”

Section: Discussionsupporting

confidence: 92%

Comparison of in vitro Activities of Tigecycline with Other Antimicrobial Agents against Streptococcus pneumoniae,Haemophilus influenzae and Moraxella catarrhalis in Two University Hospitals in Istanbul, Turkey

Gönüllü

Catal²,

Küçükbasmacı³

et al. 2009

Chemotherapy

View full text Add to dashboard Cite

Background: We compared the in vitro activities of tigecycline with those of other agents against 97 Streptococcus pneumoniae, 140 Haemophilus influenzae and54 Moraxella catarrhalis strains isolated in two large university hospitals in Istanbul. Methods: For analysis, the agar dilution method was used. Results: For S. pneumoniae isolates, 32% were not susceptible to penicillin (28.9% intermediate and 3.1% resistant). Cefotaxime, telithromycin, moxifloxacin and linezolid were fully active. Tigecycline had a 90% minimum inhibitory concentration (MIC₉₀) of 0.12 μg/ml. For H. influenzae, 8.57% were not susceptible to ampicillin, among which 8 possessed β-lactamase (5.7%). Four (2.87%) H. influenzae isolates with β-lactamase-negative and ampicillin-resistant phenotype were found. All isolates were susceptible to ceftriaxone, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin. MIC₉₀ for tigecycline was 0.5 μg/ml. Of 54 M. catarrhalis isolates, 88.9% possessed β-lactamase. Tigecycline and fluoroquinolones were highly active (MIC₉₀ ≤0.12 μg/ml). Conclusions: Linezolid, telithromycin, newer fluoroquinolones and tigecycline all have excellent in vitro activities against the 3 respiratory pathogens.

show abstract

Section: Discussionsupporting

confidence: 92%

Comparison of in vitro Activities of Tigecycline with Other Antimicrobial Agents against Streptococcus pneumoniae,Haemophilus influenzae and Moraxella catarrhalis in Two University Hospitals in Istanbul, Turkey

Gönüllü

Catal²,

Küçükbasmacı³

et al. 2009

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…were isolated in small numbers, tigecycline generally eradicated most of these pathogens. Overall, these data provide in vivo evidence that tigecycline has broad-spectrum activity against common bacterial etiologies associated with cIAIs [9,10,14,17,18]. …”

Section: Discussionmentioning

confidence: 73%

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

Chen

Zhang

et al. 2010

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundTigecycline, a first-in-class broad-spectrum glycylcycline antibiotic, has broad-spectrum in vitro activity against bacteria commonly encountered in complicated intra-abdominal infections (cIAIs), including aerobic and facultative Gram-positive and Gram-negative bacteria and anaerobic bacteria. In the current trial, tigecycline was evaluated for safety and efficacy vs. imipenem/cilastatin in hospitalized Chinese patients with cIAIs.MethodsIn this phase 3, multicenter, open-label study, patients were randomly assigned to receive IV tigecycline or imipenem/cilastatin for ≤2 weeks. The primary efficacy endpoints were clinical response at the test-of-cure visit (12-37 days after therapy) for the microbiologic modified intent-to-treat and microbiologically evaluable populations. Because the study was not powered to demonstrate non-inferiority between tigecycline and imipenem/cilastatin, no formal statistical analysis was performed. Two-sided 95% confidence intervals (CIs) were calculated for the response rates in each treatment group and for differences between treatment groups for descriptive purposes.ResultsOne hundred ninety-nine patients received ≥1 dose of study drug and comprised the modified intent-to-treat population. In the microbiologically evaluable population, 86.5% (45 of 52) of tigecycline- and 97.9% (47 of 48) of imipenem/cilastatin-treated patients were cured at the test-of-cure assessment (12-37 days after therapy); in the microbiologic modified intent-to-treat population, cure rates were 81.7% (49 of 60) and 90.9% (50 of 55), respectively. The overall incidence of treatment-emergent adverse events was 80.4% for tigecycline vs. 53.9% after imipenem/cilastatin therapy (P < 0.001), primarily due to gastrointestinal-related events, especially nausea (21.6% vs. 3.9%; P < 0.001) and vomiting (12.4% vs. 2.0%; P = 0.005).ConclusionsClinical cure rates for tigecycline were consistent with those found in global cIAI studies. The overall safety profile was also consistent with that observed in global studies of tigecycline for treatment of cIAI, as well as that observed in analyses of Chinese patients in those studies; no novel trends were observed.Trial RegistrationClinicalTrials.gov NCT00136201

show abstract

“…Pseudomonas aeruginosa is intrinsically resistant [11], and Proteus spp., Klebsiella pneumoniae, Providencia spp., M. morganii, Enterobacter spp., and E. coli may show reduced tigecycline susceptibility. Tigecycline administered in healthy subjects significantly reduced the numbers of enterococci, E. coli, lactobacilli, and bifidobacteria, and increased Candida albicans, K. pneumoniae, and E. cloacae, and some patients (7/12) presented colonization by resistant strains to tigecycline on day 8 [12].…”

Section: Discussionmentioning

confidence: 99%

Superinfection during treatment of nosocomial infections with tigecycline

García-Cabrera

Me²,

Navarro³

et al. 2010

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

We performed a retrospective and observational study of 51 patients treated with tigecycline, as the treatment for nosocomial infections due to multidrugresistant microorganisms, to evaluate the superinfection rate and their etiologies. Superinfections were diagnosed in 12 (23.5%) patients (seven due to Pseudomonas aeruginosa, 13.7%) and one patient had P. aeruginosa colonization. Five patients with superinfection died (41.6%), three due to superinfections and two to underlying diseases. The superinfection rate observed during tigecycline treatment is higher than that previously reported. Pseudomonas aeruginosa is the most frequent agent, being the cause of 58.5% of all superinfections.

show abstract

In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America

Cited by 24 publications

References 17 publications

Comparison of in vitro Activities of Tigecycline with Other Antimicrobial Agents against <i>Streptococcus pneumoniae,</i><i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis </i>in Two University Hospitals in Istanbul, Turkey

Comparison of in vitro Activities of Tigecycline with Other Antimicrobial Agents against <i>Streptococcus pneumoniae,</i><i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis </i>in Two University Hospitals in Istanbul, Turkey

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

Superinfection during treatment of nosocomial infections with tigecycline

Contact Info

Product

Resources

About